COMPARATIVE ANALYSIS OF IVIVE METHODS 4325
Data Processing and Analysis
Data collection was conducted with Analyst 1.5 soft-
ware, and data processing was performed with Multi-
quant 2.0. The percentage of protein binding or micro-
somal binding in each matrix was calculated from the
area ratio of the analyte detected (normalized to inter-
nal standard) from the receiver side responses to the
donor side multiplied by 100. Then 100% binding was
used to calculate the unbound fraction (fu). The bind-
ing ratio of AAG to AL was calculated from the area
ratio of the analyte detected (normalized to internal
standard) from the receiver side (AAG) responses to
the donor side (AL). When AAG/AL is dialysed against
each other, a ratio greater than ∼0.6 suggests AAG is
1. Wan H, Bold P, Larsson LO, Ulander J, Peters S, Lofberg B,
Ungell AL, Nagard M, Llinas A. 2010. Impact of input param-
eters on the prediction of hepatic plasma clearance using the
well-stirred model. Curr Drug Metab 11:583–594.
2. Obach RS. 1999. Prediction of human clearance of twenty-
nine drugs from hepatic microsomal intrinsic clearance data:
An examination of in vitro half-life approach and nonspeciﬁc
binding to microsomes. Drug Metab Dispos 27:1350–1359.
3. Jones HM, Houston JB. 2004. Substrate depletion approach
for determining in vitro metabolic clearance: Time dependen-
cies in hepatocyte and microsomal incubations. Drug Metab
4. De Buck SS, Sinha VK, Fenu LA, Nijsen MJ, Mackie CE,
Gilissen R. 2007. Prediction of human pharmacokinetics us-
ing physiologically-based pharmacokinetics modeling: A ret-
rospective analysis of 26 clinically tested drugs. Drug Metab
5. Hosea NA, Collard WT, Cole S, Maurer TS, Fang RX, Jones
H, Kakar SM, Nakai Y, Smith BJ, Webster R, Beaumont K.
2009. Prediction of human pharmacokinetics from preclinical
information: Comparative accuracy of quantitative prediction
approaches. J Clin Pharm 49:513–33.
6. Poulin P, Jones HM, Jones RDO, Yates JWT, Gibson CR, Chien
JY, Ring BJ, Adkison KK, He H, Vuppugalla R, Marathe P,
Fischer V, Dutta S, Sinha VK, Bj¨ornsson T, Lav´e T, Ku MS.
2011. PhRMA CPCDC initiative on predictive models of hu-
man pharmacokinetics. 1. Goals, properties of the PhRMA
dataset and comparison with literature datasets. J Pharm Sci
7. Ring B, Chien JY, Adkison KK, Jones HM, Rowland M, Jones
RDO, Yates JWT, Ku MS, Gibson CR, He H, Vuppugalla R,
Marathe P, Fischer V, Dutta S, Sinha VK, Bj
ornsson T, Lav
T, Poulin P. 2011. PhRMA CPCDC initiative on predictive
models of human pharmacokinetics. 3. Comparative assess-
ment of prediction methods of human clearance. J Pharm Sci
8. Tamaki S, Komura H, Kogayu M, Yamada S. 2011. Compar-
ative assessment of empirical and physiological approaches
on predicting human clearances. J Pharm Sci 100:1147–
9. Pelkonen O, Turpeinen M. 2007. in vitro–in vivo extrapo-
lation of hepatic clearance: Biological tools, scaling factors,
model assumptions, and correct concentrations. Xenobiotica
10. Beaumont K, Gardner I, Chapman K, Hall M, Rowland
M. 2011. Towards an integrated human clearance pre-
diction strategy that minimizes animal use. J Pharm Sci
11. Foster JA, Houston BJ, Halifax D. 2011. Comparison of in-
trinsic clearances in human liver microsomes and suspended
hepatocytes from the same donor livers: Clearance-dependent
relationship and implications for prediction of in vivo clear-
ance. Xenobiotica 41:124–136.
12. Berezhkovskiy LM. 2010. The corrected traditional equations
for calculation of hepatic clearance that account for the dif-
ference in drug ionisation in extracellular and intracellular
tissue water and the corresponding corrected PBPK equation.
J Pharm Sci 100:1167–1183.
13. Berezhkovskiy LM, Liu N, Halladay JS. 2011. Consistency
of the novel equation for determination of hepatic clearance
and drug time course in liver that account for the difference in
drug ionization in extracellular and intracellular tissue water.
J Pharm Sci 101:516–518.
14. Poulin P, Kenny JR, ECA Hop, Haddad S. 2012. in vit-
ro–in vivo extrapolation of clearance: Modeling hepatic
metabolic clearance of highly bound drugs and comparative
assessment with existing methods. J Pharm Sci 101:838–
15. Halifax D, Houston BJ. 2012. Evaluation of hepatic clearance
prediction using in vitro data: Emphasis of fraction unbound
in plasma and drug ionisation using a dataset of 107 drugs.
J Pharm Sci 101:2645–2652.
16. Benet LZ, Broccattelli F, Oprea TI. 2011. BDDCS applied to
over 900 drugs. AAPS J 32:1311–1336.
17. Paillard M, Sraer JD, Claret M, Favier MP. 1970. Mea-
surement of intracellular pH in several tissues by using the
micro-electrode speciﬁcally sensible. J Physiol (Paris) 62(Suppl
18. Rothe KF, Heisler N. 1986. Correction of metabolic alkalosis
by HCL and acetazolamide; effects on extracellular and in-
tracellular acid-base status in rats in vivo. Acta Anaesthesiol
19. Rothe VF. 1984. New aspects of acid-base balance: Inﬂuences
of plasma pH variation on intracellular tissue pH in vivo.
Fortschr Med 46:158–157.
20. Rodgers T, Rowland M. 2006. Physiologically based phar-
macokinetic modelling 2: Predicting the tissue distribution of
acids, very weak bases, neutrals and zwitterions. J Pharm Sci
21. Peyret T, Poulin P, Krishnan K. 2010. A uniﬁed algorithm
for predicting partition coefﬁcients for PBPK modeling of
drugs and environmental chemicals. Toxicol Appl Pharmacol
22. Gordon AH, Humphrey JH. 1961. Measurement of intracellu-
lar albumin in rat liver. Biochem J 78:551–556.
23. Park R, Leach WJ, Arieff AL. 1980. Measurement of the
liver extracellular space in vivo in dogs. Horm Metab Res
24. Poulin P, Theil FP. 2009. Development of a novel method for
predicting human volume of distribution at steady-state of ba-
sic drugs and comparative assessment with existing methods.
J Pharm Sci 98:4941–4961.
25. Reimann IW, Okonkwo PO, Klotz U. 1990. Pharmacokinetics
of ketanserin in man. Eur J Clin Pharmacol 25:73–76.
26. Meuldermans W, Hendrickx J, Lauwers W, Swysen E, Hurk-
mans R, Knaeps F, Woestenborghs R, Heykants J. 1984. Ex-
cretion and biotransformation of ketanserin after oral and in-
travenous administration in rats and dogs. Drug Metab Dispos
27. Lam JL, Benet LZ. 2004. Hepatic microsome studies
are insufﬁcient to characterize hepatic metabolic clearance
and metabolic drug–drug interactions: Studies of digoxin
metabolism in primary rat hepatocytes versus microsomes.
Drug Metab Dispos 32:1311–1336.
DOI 10.1002/jps JOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 101, NO. 11, NOVEMBER 2012